Compare RLMD & BOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | BOW |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.9M | 734.3M |
| IPO Year | 2012 | 2024 |
| Metric | RLMD | BOW |
|---|---|---|
| Price | $6.69 | $29.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $12.40 | ★ $32.29 |
| AVG Volume (30 Days) | ★ 1.5M | 138.5K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | 23.26 |
| EPS | N/A | ★ 0.48 |
| Revenue | $13,070.00 | ★ $551,589,000.00 |
| Revenue This Year | N/A | $21.31 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | ★ N/A | $58.88 |
| Revenue Growth | ★ 154.83 | 29.58 |
| 52 Week Low | $0.55 | $21.21 |
| 52 Week High | $8.00 | $37.98 |
| Indicator | RLMD | BOW |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 67.48 |
| Support Level | $6.17 | $23.65 |
| Resistance Level | $7.46 | N/A |
| Average True Range (ATR) | 0.45 | 1.01 |
| MACD | 0.03 | 0.23 |
| Stochastic Oscillator | 60.47 | 96.69 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.